New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2013
19:37 EDTACT, NVS, MYL, VRXNovartis weighing Actavis bid, WSJ reports
Valeant Pharmaceuticals (VRX) and Mylan (MYL) are weighing options after approaches made to Actavis (ACT) were rebuffed, and a report by the Wall Street Journal, citing a source, says Novartis (NVS) is weighing whether to launch its own bid for Actavis. Reference Link
News For NVS;MYL;VRX;ACT From The Last 14 Days
Check below for free stories on NVS;MYL;VRX;ACT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 18, 2014
07:35 EDTNVSApricus Biosciences launches topical ED treatment in Germany
Subscribe for More Information
August 15, 2014
17:03 EDTVRXValeant extends offer to acquire Allergan
Valeant Pharmaceuticals (VRX) announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of Allergan (AGN) to December 31. The exchange offer was previously scheduled to expire August 15. All other terms and conditions of the exchange offer remain unchanged.
14:14 EDTVRXValeant being probed by IRS after Biovail deal, FT says
Subscribe for More Information
09:45 EDTVRXEvent-driven funds, Pershing own over 20% of Allergan, CNBC reports
Event-driven hedge funds and Pershing Square owned over 20% of Allergan as of June 30, CNBC's David Faber reports. Valeant (VRX) and Pershing are seen as getting the over 30% to call a special meeting, Faber adds.
August 14, 2014
17:41 EDTVRXPoint72 Asset Management gives quarterly update on stakes
Subscribe for More Information
17:31 EDTACTZogenix says Actavis files ANDA for generic version of Zohydro ER
Subscribe for More Information
14:28 EDTVRXAckman says Pershing, Valeant took no tender steps before buying Allergan shares
Bill Ackman made the statement to CNBC's Scott Wapner regarding his fund and Valeant's (VRX) pursuit of Allergan (AGN). Note that the Wall Street Journal reported earlier that the SEC is investigating Valeant and Pershing's pursuit of Allergan.
14:13 EDTACTOmega Advisors gives quarterly update on stakes
Subscribe for More Information
13:48 EDTVRXValeant, Pershing joint bid for Allergan being probed by SEC, WSJ says
Subscribe for More Information
13:22 EDTVRXValeant, Pershing joint bid for Allergan being probed by SEC, DJ says
Subscribe for More Information
12:58 EDTACTJANA Partners gives quarterly update on stakes
NEW STAKES: Apache (APA), FMC Corp (FMC), Civeo (CVEO), PetSmart (PETM), and Charter Communications (CHTR). INCREASED STAKES: Actavis (ACT), AIG (AIG), Mallinckrodt (MNK), HD Supply (HDS), and American Capital (ACAS). DECREASED STAKES: Liberty (LVNTA), Oil States International (OIS), eBay (EBAY), Liberty Media (LMCA), and Liberty Interactive (LINTA). LIQUIDATED STAKES: Sirius XM (SIRI), Juniper (JNPR), Golar LNG (GLNG), Outerwall (OUTR), and Teva (TEVA).
12:46 EDTACTHayman Capital gives quarterly update on stakes
Subscribe for More Information
August 12, 2014
07:55 EDTACTActavis recent weakness a buying opportunity, says Argus
Subscribe for More Information
August 11, 2014
17:36 EDTVRXValeant receives FTC second request under Hart-Scott-Rodino
Subscribe for More Information
12:52 EDTVRXAllergan receives second request from FTC regarding Valeant's proposal
Allergan (AGN) announced that it received a request for additional information under the Hart-Scott-Rodino Act from the U.S. Federal Trade Commission in connection with Valeant Pharmaceuticals International's (VRX) unsolicited acquisition proposal of Allergan. Allergan intends to respond fully in connection with the ongoing investigation. The Company noted that Second Request investigations typically take some time to conclude, and Allergan cannot predict how long this investigation will take or how it might otherwise develop. The company previously announced that Allerganís Board of Directors unanimously determined that Valeantís unsolicited exchange offer is grossly inadequate, substantially undervalues the company, creates significant risks and uncertainties for Allergan stockholders, and is not in the best interests of the company and its stockholders. Goldman, Sachs & Co. and BofA Merrill Lynch are serving as financial advisors to the company and Latham & Watkins, Richards, Layton & Finger, P.A. and Wachtell, Lipton, Rosen & Katz are serving as legal counsel to the company.
12:42 EDTVRXValeant shareholder ValueAct sees no need to buy Allergan, Reuters says
Subscribe for More Information
12:27 EDTVRXValueAct says Valeant does not need to buy Allergan, Reuters says
Subscribe for More Information
07:36 EDTMYLMylan launches generic Xeloda tablets
Subscribe for More Information
07:22 EDTVRXJudge sets hearing date for Allergan suit vs. Valeant, Reuters reports
Subscribe for More Information
05:18 EDTNVSNovartis reports LCZ696 significantly reduced cardiovascular deaths
New data revealing the reduction in cardiovascular, or CV, deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction, or HF-REF, will be presented at the European Society of Cardiology, or ESC, Congress 2014. The 8,442 patient study, PARADIGM-HF, was specifically designed to see if LCZ696 could increase survival over and above what can be achieved with ACE-inhibitor enalapril in addition to current best treatment in HF-REF patients. In March the Data Monitoring Committee overseeing the study confirmed those given LCZ696 were significantly less likely to die from CV causes, leading to the trial being closed early. LCZ696 significantly reduced cardiovascular deaths in head to head study against enalapril, in addition to current best treatment, in patients with HF-REF. PARADIGM-HF is the largest heart failure study ever conducted and was stopped early in March due to compelling efficacy. LCZ696 was recently granted FDA Fast Track status and rolling submission expected to be complete by end of year.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use